toxic epidermal necrolysis | GenomeWeb

toxic epidermal necrolysis

Pharmigene said last week that 50 hospitals in Taiwan will now administer its test for HLA-B*1502, which is a marker for increased risk of adverse events in Asian populations treated with the anti-seizure drug carbamazepine.

The Mayo Clinic will develop tests to detect for the presence of alleles that increase the risk for developing the potentially deadly skin disease if certain drugs are taken.

The data, analyzed from biological samples donated by GlaxoSmithKline, is available on SAEC's website for free, and the group plans to publish the associations later this year. However, an SAEC official said "it would be preliminary to develop a meaningful diagnostic chip off this data."

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.